Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imugene ( (AU:IMU) ) has provided an announcement.
Imugene Limited announced that its PD1-Vaxx colorectal cancer trial will be featured at the ESMO Congress 2025, highlighting its growing international clinical presence. The Neo-POLEM Phase II trial aims to assess the efficacy of PD1-Vaxx, a novel B-cell vaccine, in treating early-stage MSI-high colorectal cancer, potentially offering an alternative to existing monoclonal antibody therapies. The trial, which began recruitment in May 2025, is a collaborative effort involving multiple sites in the UK and Australia, and seeks to improve treatment outcomes for colorectal cancer patients.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a clinical-stage immuno-oncology company focused on developing novel therapies that harness the immune system to treat cancer. The company is actively involved in creating B-cell vaccines targeting immune checkpoints, with a particular emphasis on improving treatment options for various cancers.
YTD Price Performance: -70.59%
Average Trading Volume: 3,012,382
Technical Sentiment Signal: Sell
Current Market Cap: A$109.5M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.